                         SEQUENCE LISTING

<110>  Theratechnologies Inc.
       Marsolais, Christian
        
<120>  Use of cytochrome P450-metabolized drugs and GRF molecules in combination therapy
<130>  780/11718.277

<150>  US 61/170,852
<151>  2009-04-20

<160>  7    

<170>  PatentIn version 3.3

<210>  1
<211>  44
<212>  PRT
<213>  Artificial sequence

<220>
<223>  GRF peptide

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa = Tyr or His

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa = Val or Ala

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa = Asn or Ser

<220>
<221>  VARIANT
<222>  (13)..(13)
<223>  Xaa = Val or Ile

<220>
<221>  VARIANT
<222>  (15)..(15)
<223>  Xaa = Ala or Gly

<220>
<221>  VARIANT
<222>  (18)..(18)
<223>  Xaa = Ser or Tyr

<220>
<221>  VARIANT
<222>  (24)..(24)
<223>  Xaa = Gln or His

<220>
<221>  VARIANT
<222>  (25)..(25)
<223>  Xaa = Asp or Glu

<220>
<221>  VARIANT
<222>  (27)..(27)
<223>  Xaa = Met or Ile or Nle

<220>
<221>  VARIANT
<222>  (28)..(28)
<223>  Xaa = Ser or Asn
	
<220>
<221>  VARIANT
<222>  (30)..(30)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (31)..(31)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (32)..(32)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (33)..(33)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (34)..(34)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (35)..(35)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (36)..(36)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (37)..(37)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (38)..(38)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (39)..(39)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (40)..(40)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (41)..(41)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (42)..(42)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (43)..(43)
<223>  Xaa = any amino acid or is absent

<220>
<221>  VARIANT
<222>  (44)..(44)
<223>  Xaa = any amino acid or is absent

<220>
<221>  MOD_RES
<222>  (29)..(44)
<223>  C-terminal amino acid is modified with NH2 or NH-(CH2)n-CONH2, with n=1 to 12

<400>  1

Xaa Xaa Asp Ala Ile Phe Thr Xaa Ser Tyr Arg Lys Xaa Leu Xaa Gln 
1               5                   10                  15      

Leu Xaa Ala Arg Lys Leu Leu Xaa Xaa Ile Xaa Xaa Arg Xaa Xaa Xaa 
            20                  25                  30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
        35                  40      


<210>  2
<211>  44
<212>  PRT
<213>  Homo sapiens

<220>
<221>  MISC_FEATURE
<222>  (44)..(44)
<223>  Leu residue is capped with an unsubstituted amide moiety

<400>  2

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln 
1               5                   10                  15      

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly 
            20                  25                  30          

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu 
        35                  40                  


<210>  3
<211>  44
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Amino acid sequence of human GRF

<400>  3

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln 
1               5                   10                  15      

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly 
            20                  25                  30          

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu 
        35                  40                  


<210>  4
<211>  29
<212>  PRT
<213>  Homo sapiens

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Arg residue is capped with an unsubstituted amide moiety

<400>  4

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln 
1               5                   10                  15      

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg 
            20                  25                  


<210>  5
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Amino acid sequence of minimum active core of human GRF

<400>  5

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln 
1               5                   10                  15      

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg 
            20                  25                  


<210>  6
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Amino acid sequence corresponding to positions 30 to 44 of human 
       GRF

<400>  6

Gln Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu 
1               5                   10                  15  


<210>  7
<211>  44
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Modified GRF peptide

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Tyr residue is linked to a trans-3-hexenoyl moiety

<220>
<221>  MISC_FEATURE
<222>  (44)..(44)
<223>  Leu residue is capped with an unsubstituted amide moiety

<400>  7

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln 
1               5                   10                  15      

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly 
            20                  25                  30          

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu 
        35                  40                  



